Peter Alping
Peter Alping
Verifierad e-postadress på ki.se
Titel
Citeras av
Citeras av
År
Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy
J Salzer, R Svenningsson, P Alping, L Novakova, A Björck, K Fink, ...
Neurology 87 (20), 2074-2081, 2016
1692016
Rituximab versus fingolimod after natalizumab in multiple sclerosis patients
P Alping, T Frisell, L Novakova, P Islam‐Jakobsson, J Salzer, A Björck, ...
Annals of neurology 79 (6), 950-958, 2016
1432016
Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies
G Luna, P Alping, J Burman, K Fink, A Fogdell-Hahn, M Gunnarsson, ...
JAMA neurology 77 (2), 184-191, 2020
652020
Validation of the Swedish Multiple Sclerosis Register: further improving a resource for pharmacoepidemiologic evaluations
P Alping, F Piehl, A Langer-Gould, T Frisell
Epidemiology (Cambridge, Mass.) 30 (2), 230, 2019
122019
Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients
P Alping, J Askling, J Burman, K Fink, A Fogdell‐Hahn, M Gunnarsson, ...
Annals of Neurology 87 (5), 688-699, 2020
82020
Cancer risk among Swedish multiple sclerosis patients: a nationwide cohort study comparing rituximab, fingolimod and natalizumab.
P Alping, F Piehl, T Frisell
MULTIPLE SCLEROSIS JOURNAL 24, 36-36, 2018
42018
Rituximab does not increase the risk of malignancy or breast cancer in two large US and Swedish rituximab-treated multiple sclerosis cohorts
A Langer-Gould, P Alping, J Smith, B Li, F Piehl, T Frisell
MULTIPLE SCLEROSIS JOURNAL 25, 570-571, 2019
2019
Disease-modifying therapies for multiple sclerosis in association with pregnancy: a Swedish nation-wide cohort study
A Gorczyca, P Alping, T Frisell, F Piehl, A Langer-Gould, K Fink
MULTIPLE SCLEROSIS JOURNAL 24, 146-147, 2018
2018
Baseline characteristics from the COMBAT-MS study: Initial analyses suggest main driver for therapy choice is geographic location
P Alping, J Burman, K Fink, M Gunnarsson, J Lycke, P Nilsson, J Salzer, ...
Multiple Sclerosis 23, 714-714, 2017
2017
Rituximab in multiple sclerosis; data from the swedish MS registry.
P Alping, A Svenningsson, J Salzer, J Burman, C Dahle, K Fink, J Hillert, ...
Multiple Sclerosis 22 (suppl. 3), 49-49, 2016
2016
Systemet kan inte utföra åtgärden just nu. Försök igen senare.
Artiklar 1–10